InvestorsHub Logo
Followers 35
Posts 7963
Boards Moderated 1
Alias Born 04/04/2020

Re: JRoon71 post# 437188

Saturday, 07/05/2025 10:16:02 PM

Saturday, July 05, 2025 10:16:02 PM

Post# of 437357
JRoon, You clearly don't understand the ruling in GSK v Teva. First explain how there is no overlap between the two Vascepa indications. If you can't, explain how that overlap wouldn't invalidate all generic "skinny labels".
Sleven,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News